

# MARCKS protein mediates hydrogen peroxide regulation of endothelial permeability

Benjamin Y. Jin<sup>a,b</sup>, Alison J. Lin<sup>a,b,c,1</sup>, David E. Golan<sup>b,c,1</sup>, and Thomas Michel<sup>a,1</sup>

<sup>a</sup>Cardiovascular Division and <sup>c</sup>Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115; and <sup>b</sup>Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115

Edited by Michael A. Marletta, University of California, Berkeley, CA, and approved August 7, 2012 (received for review March 26, 2012)

**Impairment of endothelial barrier function is implicated in many vascular and inflammatory disorders. One prevalent mechanism of endothelial dysfunction is an increase in reactive oxygen species under oxidative stress. Previous reports have demonstrated that hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), a highly stable reactive oxygen species that modulates physiological signaling pathways, also enhances endothelial permeability, but the mechanism of this effect is unknown. Here, we identify the actin-binding protein myristoylated alanine-rich C-kinase substrate (MARCKS) as a key mediator of the H<sub>2</sub>O<sub>2</sub>-induced permeability change in bovine aortic endothelial cells. MARCKS knockdown and H<sub>2</sub>O<sub>2</sub> treatment alter the architecture of the actin cytoskeleton in endothelial cells, and H<sub>2</sub>O<sub>2</sub> induces the phosphorylation and translocation of MARCKS from the cell membrane to the cytosol. Using pharmacological inhibitors and small interference RNA constructs directed against specific proteins, we uncover a signaling cascade from Rac1 to Abl1, phospholipase C $\gamma$ 1, and PKC $\delta$  that is triggered by H<sub>2</sub>O<sub>2</sub> and leads to MARCKS phosphorylation. Our findings establish a distinct role for MARCKS in the regulation of H<sub>2</sub>O<sub>2</sub>-induced permeability change in endothelial cells, and suggest potential new therapeutic targets for the treatment of disorders involving oxidative stress and altered endothelial permeability.**

The vascular endothelium forms the inner lining of blood vessels and functions as a selective barrier for transport of macromolecules and circulating cells (1, 2). Endothelial cells maintain barrier function by sustaining the integrity of the vessel wall. Multiple mediators affect the barrier function of endothelial cells. One family of mediators consists of the reactive oxygen species (ROS) (3) hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and superoxide anion. ROS have physiological roles at lower concentrations, but higher concentrations of ROS induce oxidative stress and contribute to the pathophysiology of vascular diseases (4, 5), in part by causing endothelial barrier dysfunction (6, 7).

H<sub>2</sub>O<sub>2</sub> is a cell-permeant and stable ROS generated mainly by the dismutation of superoxide anion by superoxide dismutases. H<sub>2</sub>O<sub>2</sub> modulates diverse physiological processes in endothelial cells, including cytoskeletal reorganization, as well as vascular remodeling and vasorelaxation (8–10). The molecular mechanisms by which H<sub>2</sub>O<sub>2</sub> affects these endothelial cell functions are incompletely understood. Treatment of endothelial cells with H<sub>2</sub>O<sub>2</sub> modulates diverse signaling pathways (11–13), but the pathways that regulate actin polymerization and cytoskeletal reorganization have not been elucidated.

The MARCKS (myristoylated alanine-rich C-kinase substrate) protein is expressed in neuronal tissues and endothelial cells, where the protein has been implicated in the regulation of cell attachment and affects the directed migration of endothelial cells (14–16). MARCKS binds to actin and to calcium/calmodulin, and interacts with membrane phospholipids (17, 18). The binding of membrane phospholipids by MARCKS enables MARCKS association with the cell membrane. PKC-mediated MARCKS phosphorylation causes MARCKS to dissociate from the membrane and inhibits its ability to cross-link F-actin (18, 19). MARCKS's function as both a PKC substrate and an actin-regulating protein suggest that MARCKS could be a mediator in the regulation of H<sub>2</sub>O<sub>2</sub>-stimulated cytoskeletal reorganization in endothelial cells.

Here we study the regulation of endothelial permeability and cytoskeletal organization by H<sub>2</sub>O<sub>2</sub>. MARCKS is identified as a mediator of the H<sub>2</sub>O<sub>2</sub>-induced endothelial permeability change. MARCKS and H<sub>2</sub>O<sub>2</sub> also affect the architecture of the actin cytoskeleton in endothelial cells. MARCKS is phosphorylated in response to H<sub>2</sub>O<sub>2</sub> in a dose- and time-dependent manner, and H<sub>2</sub>O<sub>2</sub> induces MARCKS translocation from the cell membrane to the cytosol. Experiments using small interference-(siRNA) targeting constructs identify an H<sub>2</sub>O<sub>2</sub>-induced Rac1/Abl1/phospholipase C (PLC) $\gamma$ 1/PKC $\delta$  signaling cascade that leads to MARCKS phosphorylation in endothelial cells. Our studies establish a unique role for MARCKS in regulating endothelial permeability.

## Results

**MARCKS Is an Important Mediator of the H<sub>2</sub>O<sub>2</sub>-Induced Endothelial Permeability Change and Actin Cytoskeleton Reorganization.** We explored the role of MARCKS in the H<sub>2</sub>O<sub>2</sub>-induced increase in endothelial permeability, using a siRNA construct to specifically knock down MARCKS expression in bovine aortic endothelial cells (BAECs) (20). BAECs were chosen for these studies because of their phenotypic stability in cell culture and their well-characterized signaling pathways. We measured the H<sub>2</sub>O<sub>2</sub>-induced endothelial permeability change using a FITC-Dextran assay. BAECs transfected with MARCKS siRNA showed reduced MARCKS expression (Fig. S1). In the absence of H<sub>2</sub>O<sub>2</sub>, siRNA-mediated knockdown of MARCKS had no effect on endothelial permeability (Fig. 1A). In response to H<sub>2</sub>O<sub>2</sub>, cells transfected with control siRNA showed a significant increase in endothelial permeability; cells transfected with MARCKS siRNA did not show an increase in endothelial permeability for up to 3 h after H<sub>2</sub>O<sub>2</sub> treatment. Four hours after H<sub>2</sub>O<sub>2</sub> treatment, BAECs transfected with MARCKS siRNA did show a significant increase in endothelial permeability compared with untreated cells ( $n = 4$ ,  $P < 0.05$ ). However, the increase in permeability in H<sub>2</sub>O<sub>2</sub>-treated cells transfected with MARCKS siRNA was significantly less than in H<sub>2</sub>O<sub>2</sub>-treated cells transfected with control siRNA ( $n = 4$ ,  $P < 0.05$ ) (Fig. 1A). H<sub>2</sub>O<sub>2</sub> induced a dose-dependent increase in endothelial permeability that was suppressed by siRNA-mediated MARCKS knockdown (Fig. 1B), with no change in endothelial cell viability. These results suggested that MARCKS is a mediator of the H<sub>2</sub>O<sub>2</sub>-induced endothelial permeability change, but does not modulate changes in basal permeability (Fig. 1).

We next examined the role of MARCKS in H<sub>2</sub>O<sub>2</sub>-mediated cytoskeletal reorganization. BAECs transfected with control or MARCKS siRNA were stained with Alexa Fluor-488 phalloidin to image the actin cytoskeleton. Endothelial cells contain stress fibers that form when bundles of actin filaments extend from the


Author contributions: B.Y.J., A.J.L., and T.M. designed research; B.Y.J. and A.J.L. performed research; B.Y.J., A.J.L., D.E.G., and T.M. analyzed data; and B.Y.J., A.J.L., D.E.G., and T.M. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

<sup>1</sup>To whom correspondence may be addressed. E-mail: thomas\_michel@harvard.edu, david\_golan@hms.harvard.edu, or linaj@mail.nih.gov.

This article contains supporting information online at [www.pnas.org/lookup/suppl/doi:10.1073/pnas.1204974109/-DCSupplemental](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1204974109/-DCSupplemental).



**Fig. 1.** MARCKs regulates endothelial permeability and cytoskeleton organization. (A) BAECs were transfected with control siRNA (diamond and square) or MARCKs siRNA (triangle and star), and endothelial permeability was assessed using the FITC-dextran assay. Cells were treated with vehicle (diamond and triangle) or with 200  $\mu\text{M}$   $\text{H}_2\text{O}_2$  (square and star). The plot shows the fluorescence intensity of FITC-dextran ( $n = 4$ ). \* $P < 0.05$  vs. control siRNA; # $P < 0.05$  vs. MARCKs siRNA; § $P < 0.05$  vs. MARCKs siRNA+ $\text{H}_2\text{O}_2$ . (B) Cells transfected with control siRNA or with MARCKs siRNA were treated with vehicle or with  $\text{H}_2\text{O}_2$  at varying concentrations as indicated and analyzed for permeability. The plot shows the fluorescence intensity of FITC-dextran ( $n = 3$ ). \* $P < 0.05$  vs. control siRNA. (C) BAECs were fixed, stained with Alexa Fluor-488 phalloidin, and imaged using a 60 $\times$  objective. Cells transfected with control siRNA were treated with vehicle (i) or with 200  $\mu\text{M}$   $\text{H}_2\text{O}_2$  (ii) for 30 min; cells transfected with MARCKs siRNA were treated with vehicle (iii) or with 200  $\mu\text{M}$   $\text{H}_2\text{O}_2$  (iv) for 30 min. The open arrow demonstrates stress fibers; the solid arrow shows cortical actin. (D) BAECs were fixed and stained with Alexa Fluor-568 phalloidin to label actin. Cells transfected with control siRNA were treated with vehicle (i) or with 5  $\mu\text{M}$  cytochalasin D (ii) for 15 min; cells transfected with MARCKs siRNA were treated with vehicle (iii) or with 5  $\mu\text{M}$  cytochalasin D (iv) for 15 min.

cell surface through the cytosol (19). Actin stress fibers play an important role in regulating cellular adhesion, morphology, and permeability. Both siRNA-mediated knockdown of MARCKs and treatment with  $\text{H}_2\text{O}_2$  increased the presence of actin stress fibers in BAECs (Fig. 1C). Compared with the actin stress fibers in BAECs transfected with MARCKs siRNA or treated with  $\text{H}_2\text{O}_2$ , the actin stress fibers in  $\text{H}_2\text{O}_2$ -treated BAECs transfected with MARCKs siRNA were more pronounced. In contrast, cortical actin, which is found just beneath the plasma membrane and is a key determinant of cell shape, was less evident in  $\text{H}_2\text{O}_2$ -treated BAECs transfected with control siRNA, and was more prominent in both untreated and  $\text{H}_2\text{O}_2$ -treated BAECs transfected with MARCKs siRNA (Fig. 1C). Treatment with cytochalasin D, which inhibits actin polymerization and promotes its depolymerization (21), disrupted the actin cytoskeleton in BAECs transfected with control siRNA (Fig. 1D). MARCKs knockdown mitigated the effect of cytochalasin D and preserved the cortical actin, enabling the cell to better retain its shape (Fig. 1D). These findings indicated the importance of MARCKs not only in the basal regulation of the actin cytoskeleton, but also in  $\text{H}_2\text{O}_2$ -modulated cytoskeletal reorganization.


**$\text{H}_2\text{O}_2$  Induces MARCKs Phosphorylation and Translocation in Endothelial Cells.** MARCKs phosphorylation and localization affect its binding partners and function (13, 18). We next characterized the effects of  $\text{H}_2\text{O}_2$  on MARCKs phosphorylation and localization. Endothelial cells were treated with varying concentrations of  $\text{H}_2\text{O}_2$ , and cell lysates were analyzed in immunoblots probed with phospho-MARCKs and total MARCKs antibodies.  $\text{H}_2\text{O}_2$  treatment increased MARCKs phosphorylation in a dose-dependent manner, without affecting total MARCKs abundance (Fig. 2A). MARCKs was phosphorylated within 15 min after addition of  $\text{H}_2\text{O}_2$ , and this signal was sustained for at least 60 min (Fig. 2B).

Phosphorylated MARCKs disassociates from the plasma membrane and translocates to the cytosol (13). We transfected BAECs with a plasmid encoding a MARCKs-GFP fusion protein and used laser confocal microscopy to image the fluorescent MARCKs construct. In untreated endothelial cells, almost all of

the MARCKs-GFP protein was detected at the plasma membrane (Fig. 2C). Within 10 min after addition of  $\text{H}_2\text{O}_2$ , we observed a marked decrease in membrane-associated MARCKs-GFP accompanied by an increase in cytosolic MARCKs-GFP; the enhancement in cytosolic fluorescence was sustained for at least 60 min. Taken together, our results showed that  $\text{H}_2\text{O}_2$  promotes MARCKs phosphorylation and induces MARCKs translocation from the plasma membrane to the cytosol.

**PKC $\delta$  Is Required for  $\text{H}_2\text{O}_2$ -Induced MARCKs Phosphorylation.** The PKC family can catalyze the phosphorylation of MARCKs (17). We used a PKC inhibitor, Gö6983, to study the role of PKC in  $\text{H}_2\text{O}_2$ -modulated MARCKs phosphorylation in BAECs. Treatment with Gö6983 attenuated basal MARCKs phosphorylation and blocked the  $\text{H}_2\text{O}_2$ -induced increase in MARCKs phosphorylation (Fig. 3A). Many different PKC isoforms have been identified in mammals (22, 23); of these, the  $\alpha$ ,  $\delta$ , and  $\epsilon$  isoforms are dominantly expressed in BAECs (24). We designed and validated siRNAs to knock down these PKC isoforms (Fig. 3B and Fig. S2). siRNA-mediated knockdown of PKC $\delta$  abrogated MARCKs phosphorylation and suppressed MARCKs phosphorylation in response to  $\text{H}_2\text{O}_2$  (Fig. 3B). In contrast, siRNA-mediated knockdown of either PKC $\alpha$  or PKC $\epsilon$  had no effect on MARCKs phosphorylation (Fig. S2). These results established PKC $\delta$  as the critical isoform involved in MARCKs phosphorylation in response to  $\text{H}_2\text{O}_2$ .

We next examined the role of PKC $\delta$  in endothelial permeability. As previously reported (25), siRNA-mediated knockdown of PKC $\delta$  increased endothelial permeability (Fig. 3C). However, the  $\text{H}_2\text{O}_2$ -induced increase in endothelial permeability was absent in BAECs following siRNA-mediated PKC $\delta$  knockdown, implicating PKC $\delta$ -mediated MARCKs phosphorylation in the  $\text{H}_2\text{O}_2$ -enhanced endothelial permeability change. Phosphorylation of membrane-associated MARCKs requires the recruitment of the upstream kinases to the cell membrane. Confocal imaging using a PKC $\delta$  isoform-specific antibody showed that PKC $\delta$  was located mainly in the cytoplasmic region in the basal state (Fig. S2C). Addition of  $\text{H}_2\text{O}_2$  induced PKC $\delta$  translocation to the plasma membrane (Fig. S2C, Center and Right). The recruitment



**Fig. 2.** H<sub>2</sub>O<sub>2</sub> induces dose-dependent and time-dependent MARCKS phosphorylation and translocation. (A) BAECs were treated with various concentrations of H<sub>2</sub>O<sub>2</sub> for 30 min and analyzed in immunoblots. (Upper) A representative immunoblot; (Lower) pooled data from five independent experiments. (B) BAECs were treated with 200 μM H<sub>2</sub>O<sub>2</sub> for various times and analyzed in immunoblots. (Upper) A representative immunoblot; (Lower) pooled data from eight independent experiments. \**P* < 0.05; \*\**P* < 0.01. (C) BAECs were transfected with MARCKS-GFP, treated with 200 μM H<sub>2</sub>O<sub>2</sub> for the indicated times, and imaged using a 60× objective. (Upper) MARCKS-GFP fluorescence; (Lower) overlay images of MARCKS-GFP (green) with differential interference contrast images of the same cells (grayscale).


of PKCδ to the plasma membrane in response to H<sub>2</sub>O<sub>2</sub> could facilitate MARCKS phosphorylation.

**PLCγ1 Regulates H<sub>2</sub>O<sub>2</sub>-Induced MARCKS Phosphorylation.** PKCδ is an atypical PKC isoform, the activation of which is independent of calcium but remains dependent on diacylglycerol (26). Because a rapid increase in diacylglycerol results mainly from PLC activity, we used the PLC inhibitor U73122 to assess the role of PLC in MARCKS phosphorylation. As shown in Fig. 4A, treatment with U73122 completely suppressed MARCKS phosphorylation. Because PLC is also activated by calmodulin-dependent protein kinase II (CaMKII) (27), which in turn can be activated by H<sub>2</sub>O<sub>2</sub>, we studied the specific CaMKII inhibitor KN93. We found that KN93 has no effect on MARCKS phosphorylation (Fig. S3), suggesting that H<sub>2</sub>O<sub>2</sub> induces MARCKS phosphorylation independent of CaMKII activation.

PLC has multiple isoforms, and BAECs express the β1, β2, γ1, and δ1 isoforms (28); of these, the PLCγ1 isoform is activated by both receptor and nonreceptor tyrosine kinases (28). Because H<sub>2</sub>O<sub>2</sub> has been implicated in activating several protein tyrosine

kinases (29), we hypothesized that PLCγ1 could play a role in H<sub>2</sub>O<sub>2</sub>-induced MARCKS phosphorylation. siRNA-mediated knockdown of PLCγ1 suppressed H<sub>2</sub>O<sub>2</sub>-induced MARCKS phosphorylation but had no effect on basal phosphorylation (Fig. 4B). Furthermore, PKCδ phosphorylation at Thr505, an indicator of PKCδ activation, was reduced in BAECs transfected with PLCγ1 siRNA and stimulated with H<sub>2</sub>O<sub>2</sub> (Fig. 4B). These results suggested that PLCγ1 activation is upstream of PKCδ-mediated MARCKS phosphorylation by H<sub>2</sub>O<sub>2</sub>.


**Activation of Abl1 Is Upstream of PLCγ1/ PKCδ-Mediated MARCKS Phosphorylation by H<sub>2</sub>O<sub>2</sub>.** The involvement of PLCγ1 in H<sub>2</sub>O<sub>2</sub>-induced MARCKS phosphorylation led us to investigate protein tyrosine kinase activation. We used the protein tyrosine kinase inhibitor bosutinib, which blocks Abl1 protein tyrosine kinase activation (30). As shown in Fig. 5A, treatment with bosutinib suppressed H<sub>2</sub>O<sub>2</sub>-induced MARCKS phosphorylation and PKCδ activation. siRNA-mediated knockdown of Abl1 suppressed H<sub>2</sub>O<sub>2</sub>-induced MARCKS phosphorylation but had no effect on basal MARCKS phosphorylation (Fig. 5B). H<sub>2</sub>O<sub>2</sub> activation of



**Fig. 3.** PKCδ is the upstream kinase for H<sub>2</sub>O<sub>2</sub>-mediated MARCKS phosphorylation. (A) BAECs were pretreated with the PKC inhibitor G66983 (10 μM, 30 min) and then treated with H<sub>2</sub>O<sub>2</sub> (200 μM, 30 min). Shown is a representative immunoblot of phosphorylated and total MARCKS. (B) BAECs were transfected with PKCδ or control siRNA, and treated with H<sub>2</sub>O<sub>2</sub> (200 μM) for various times. A representative immunoblot (Upper) and pooled data (Lower) from three independent experiments are shown. \**P* < 0.05; \*\**P* < 0.01 vs. time = 0 (solid bars) or vs. control siRNA (gray bars). (C) BAECs were transfected with control siRNA (diamond and square) or PKCδ siRNA (solid circle and cross), and endothelial permeability was assessed. Cells were treated with vehicle (diamond and solid circle) or with 200 μM H<sub>2</sub>O<sub>2</sub> (square and cross). The plot shows the fluorescence intensity of FITC-dextran (*n* = 3). \**P* < 0.05 vs. control siRNA.







**Fig. 6.** Rac1 is an early component of the  $H_2O_2$ -initiated signaling cascade leading to MARCKS phosphorylation. BAECs were transfected with Rac1 or control siRNA, treated with  $H_2O_2$  (200  $\mu M$ ) for the indicated times, and analyzed in immunoblots probed with antibodies against phospho-MARCKS, phospho-PKC $\delta$ , phospho-PLC $\gamma$ 1, phospho-Abl1, and other antibodies as shown. Panels show representative immunoblots and the pooled data from three independent experiments. \* $P < 0.05$ .

in these studies has been validated (20), and off-target effects seem unlikely given the specificity and potency with which this targeting construct promotes MARCKS knockdown, as revealed both in these studies and in our previous work (20). However, as with any study using RNA interference approaches, it is difficult to entirely exclude any off-target effects. In agreement with studies of human pulmonary artery endothelial cells (16), our studies in BAECs show that siRNA-mediated knockdown of MARCKS has no effect on basal cellular permeability. It is only in the case of the  $H_2O_2$ -enhanced endothelial permeability increase that MARCKS exhibits a significant effect.


Cellular permeability and cytoskeletal reorganization are intricately regulated in endothelial cells (5). Actin filaments play a key role in endothelial barrier function, yet the precise mechanism of actin modulation is unknown (34). Increases in endothelial permeability have been associated with an increase in stress fibers and a disruption of cortical actin (34). Conversely, studies of dominant-negative Rac1 in human umbilical vein endothelial cells have found increased permeability accompanied by decreased stress fiber formation, indicating that stress fiber formation is not essential for enhanced endothelial permeability (35). These studies highlight the complex nature of the role of cellular actin with respect to endothelial permeability regulation.

The proteins that regulate actin redistribution in the context of the  $H_2O_2$ -induced increase in endothelial permeability are incompletely understood. MARCKS is an actin-binding protein that modulates actin cytoskeletal organization in various cell types (14, 18). As shown in Fig. 1C, we saw robust actin stress fiber formation along with increased cortical actin in cells transfected with MARCKS siRNA and treated with  $H_2O_2$ . Furthermore, cells transfected with MARCKS siRNA show a sustained cortical actin structure and cell shape following treatment with cytochalasin D. Our findings indicate that  $H_2O_2$  induces an increase in stress fiber formation, a phenomenon that is shared by MARCKS knockdown. However, MARCKS knockdown also preserves cortical actin even in the presence of  $H_2O_2$ , which may facilitate the suppression of the  $H_2O_2$ -induced permeability increase seen following siRNA-mediated MARCKS knockdown. The differences in the time courses of actin remodeling and changes in permeability may reflect the broad range of cellular responses that must be marshaled to alter cellular permeability. Clearly, the relationships between actin remodeling and endothelial permeability are complex.

Cellular migration, wound healing, and permeability may be regulated by MARCKS phosphorylation (15, 20, 36). The phosphorylation of MARCKS appears to be the fundamental molecular mechanism that determines both its subcellular localization and its interactions with key structural and signaling molecules. Agents that increase endothelial permeability, such as thrombin and diacylglycerol (37–39), also induce MARCKS phosphorylation in endothelial cells (40, 41), suggesting a link between MARCKS phosphorylation and permeability. We have

characterized MARCKS phosphorylation pathways in BAECs treated with  $H_2O_2$  and have found that  $H_2O_2$  induces MARCKS phosphorylation and translocation from membrane to cytosol (Fig. 2). We have established a chain of signaling events—beginning with activation of Rac1 and followed by activation of Abl1, PLC $\gamma$ 1, and PKC $\delta$ —that result in MARCKS phosphorylation (Fig. 7). Rac1, Abl1, PLC, and PKC have all been implicated in the regulation of permeability (10, 25, 34, 35, 42, 43). Our results indicate a significant role for PKC $\delta$ -mediated MARCKS phosphorylation in the  $H_2O_2$ -induced endothelial permeability increase. In contrast to MARCKS, PKC $\delta$  also appears to modulate basal permeability, suggesting that this kinase may have an even broader role in control of vascular permeability. Taken together, these findings suggest that Rac1/Abl1/PLC $\gamma$ 1/PKC $\delta$ -mediated MARCKS phosphorylation may serve as an important mechanism in the regulation of the  $H_2O_2$ -induced endothelial permeability increase.

Low levels of endogenous  $H_2O_2$  are necessary for endothelial cell proliferation and differentiation, but high  $H_2O_2$  concentrations cause oxidative stress and endothelial dysfunction (7, 8), including alterations in endothelial permeability. Signaling molecules including PKC, PLC, Abl1, and Rho GTPase modulate endothelial permeability (10, 42–44). In addition, molecules such as PKC, Rho GTPase, and phosphatidylinositol 4,5-bisphosphate (PIP $_2$ ) regulate actin reorganization, which in turn modulates endothelial permeability. MARCKS, an actin- and PIP $_2$ -binding protein and a substrate of PKC, is an excellent candidate mediator of actin reorganization and permeability change in endothelial cells. Here, we find that MARCKS is a unique mediator of the  $H_2O_2$ -induced endothelial permeability change and actin



**Fig. 7.** A model for  $H_2O_2$ -modulated permeability increase and cytoskeleton reorganization via MARCKS phosphorylation in endothelial cells. This figure shows a model for  $H_2O_2$  modulation of endothelial permeability and cytoskeleton rearrangement via MARCKS phosphorylation in endothelial cells. Data presented in this article indicate that  $H_2O_2$  promotes MARCKS phosphorylation through a Rac1/Abl1/PLC $\gamma$ 1/PKC $\delta$  signaling pathway, associated with increased endothelial permeability and cytoskeleton reorganization. Some of the components of this pathway, such as PKC $\delta$ , may have additional roles in the modulation of basal endothelial permeability (see *Discussion*).

reorganization in endothelial cells. The MARCKS phosphorylation response involves a signaling cascade from Rac1 to Abl1, PLC $\gamma$ 1, and PKC $\delta$ . The MARCKS signaling cascade established in these studies may lead to the identification of candidate therapeutic targets for diseases involving altered endothelial permeability.

## Materials and Methods

**Materials.** Reagents are described in detail in *SI Materials and Methods*. The MARCKS-GFP plasmid was a generous gift from Debbie Stumpo and Perry Blackshear (National Institute for Environmental Health Sciences).

**Cell Culture, siRNA Transfection, and Immunoblotting.** Cells were cultured as described previously (9, 10). Details of siRNA transfection and immunoblot analysis are described in *SI Materials and Methods*.

- Aird WC (2007) Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. *Circ Res* 100:158–173.
- Bates DO (2010) Vascular endothelial growth factors and vascular permeability. *Cardiovasc Res* 87:262–271.
- Alom-Ruiz SP, Anilkumar N, Shah AM (2008) Reactive oxygen species and endothelial activation. *Antioxid Redox Signal* 10:1089–1100.
- Thomas SR, Witting PK, Drummond GR (2008) Redox control of endothelial function and dysfunction: Molecular mechanisms and therapeutic opportunities. *Antioxid Redox Signal* 10:1713–1765.
- Mehta D, Malik AB (2006) Signaling mechanisms regulating endothelial permeability. *Physiol Rev* 86:279–367.
- Stocker R, Kearney JF, Jr. (2005) New insights on oxidative stress in the artery wall. *J Thromb Haemost* 3:1825–1834.
- Cai H (2005) Hydrogen peroxide regulation of endothelial function: Origins, mechanisms, and consequences. *Cardiovasc Res* 68:26–36.
- Ardanaz N, Pagano PJ (2006) Hydrogen peroxide as a paracrine vascular mediator: Regulation and signaling leading to dysfunction. *Exp Biol Med (Maywood)* 231:237–251.
- Jin BY, Sartoretto JL, Gladyshev VN, Michel T (2009) Endothelial nitric oxide synthase negatively regulates hydrogen peroxide-stimulated AMP-activated protein kinase in endothelial cells. *Proc Natl Acad Sci USA* 106:17343–17348.
- Siflinger-Birnboim A, Goligorsky MS, Del Vecchio PJ, Malik AB (1992) Activation of protein kinase C pathway contributes to hydrogen peroxide-induced increase in endothelial permeability. *Lab Invest* 67:24–30.
- Hippenstiel S, et al. (1997) Glucosylation of small GTP-binding Rho proteins disrupts endothelial barrier function. *Am J Physiol* 272:L38–L43.
- Usatyuk PV, et al. (2003) Redox regulation of reactive oxygen species-induced p38 MAP kinase activation and barrier dysfunction in lung microvascular endothelial cells. *Antioxid Redox Signal* 5:723–730.
- Arbuzova A, Schmitz AA, Vergères G (2002) Cross-talk unfolded: MARCKS proteins. *Biochem J* 362:1–12.
- Monahan TS, et al. (2009) MARCKS silencing differentially affects human vascular smooth muscle and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein. *FASEB J* 23:557–564.
- Gatlin JC, Estrada-Bernal A, Sanford SD, Pfenninger KH (2006) Myristoylated, alanine-rich C-kinase substrate phosphorylation regulates growth cone adhesion and pathfinding. *Mol Biol Cell* 17:5115–5130.
- Guo Y, et al. (2007) Quantitative proteomics analysis of human endothelial cell membrane rafts: Evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement. *Mol Cell Proteomics* 6:689–696.
- Aderem A (1992) The MARCKS brothers: A family of protein kinase C substrates. *Cell* 71:713–716.
- Hartwig JH, et al. (1992) MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. *Nature* 356:618–622.
- Larsson C (2006) Protein kinase C and the regulation of the actin cytoskeleton. *Cell Signal* 18:276–284.
- Kalwa H, Michel T (2011) The MARCKS protein plays a critical role in phosphatidylinositol 4,5-bisphosphate metabolism and directed cell movement in vascular endothelial cells. *J Biol Chem* 286:2320–2330.
- Casella JF, Flanagan MD, Lin S (1981) Cytochalasin D inhibits actin polymerization and induces depolymerization of actin filaments formed during platelet shape change. *Nature* 293:302–305.
- Nishizuka Y (1988) The molecular heterogeneity of protein kinase C and its implications for cellular regulation. *Nature* 334:661–665.
- Perletti G, Terrian DM (2006) Distinctive cellular roles for novel protein kinase C isoenzymes. *Curr Pharm Des* 12:3117–3133.
- Rask-Madsen C, King GL (2008) Differential regulation of VEGF signaling by PKC- $\alpha$  and PKC- $\epsilon$  in endothelial cells. *Arterioscler Thromb Vasc Biol* 28:919–924.
- Tinsley JH, Teasdale NR, Yuan SY (2004) Involvement of PKC $\delta$  and PKD in pulmonary microvascular endothelial cell hyperpermeability. *Am J Physiol Cell Physiol* 286:C105–C111.
- Stahelin RV, et al. (2004) Mechanism of diacylglycerol-induced membrane targeting and activation of protein kinase C $\delta$ . *J Biol Chem* 279:29501–29512.
- Hook SS, Means AR (2001) Ca(2+)/CaM-dependent kinases: From activation to function. *Annu Rev Pharmacol Toxicol* 41:471–505.
- Rhee SG (2001) Regulation of phosphoinositide-specific phospholipase C. *Annu Rev Biochem* 70:281–312.
- Kevil CG, Okayama N, Alexander JS (2001) H(2)O(2)-mediated permeability II: importance of tyrosine phosphatase and kinase activity. *Am J Physiol Cell Physiol* 281:C1940–C1947.
- Schenone S, Brullo C, Musumeci F, Botta M (2010) Novel dual Src/Abl inhibitors for hematologic and solid malignancies. *Expert Opin Investig Drugs* 19:931–945.
- Levine YC, Li GK, Michel T (2007) Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK  $\rightarrow$  Rac1  $\rightarrow$  Akt  $\rightarrow$  endothelial nitric-oxide synthase pathway. *J Biol Chem* 282:20351–20364.
- Gonzalez E, Kou R, Michel T (2006) Rac1 modulates sphingosine 1-phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells. *J Biol Chem* 281:3210–3216.
- Zhao Y, Davis HW (1998) Hydrogen peroxide-induced cytoskeletal rearrangement in cultured pulmonary endothelial cells. *J Cell Physiol* 174:370–379.
- Lum H, Roebuck KA (2001) Oxidant stress and endothelial cell dysfunction. *Am J Physiol Cell Physiol* 280:C719–C741.
- Wójciak-Stothard B, Potempa S, Eichholtz T, Ridley AJ (2001) Rho and Rac but not Cdc42 regulate endothelial cell permeability. *J Cell Sci* 114:1343–1355.
- Estrada-Bernal A, Gatlin JC, Sunpaweravong S, Pfenninger KH (2009) Dynamic adhesions and MARCKS in melanoma cells. *J Cell Sci* 122:2300–2310.
- van der Heijden M, et al. (2011) Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells. *PLoS ONE* 6:e23448.
- Bogatcheva NV, Garcia JG, Verin AD (2002) Molecular mechanisms of thrombin-induced endothelial cell permeability. *Biochemistry (Mosc)* 67:75–84.
- Taher MM, Garcia JG, Natarajan V (1993) Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. *Arch Biochem Biophys* 303:260–266.
- Zhao Y, Davis HW (1996) Thrombin-induced phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in bovine pulmonary artery endothelial cells. *J Cell Physiol* 169:350–357.
- Coffey ET, Herrero I, Sihra TS, Sánchez-Prieto J, Nicholls DG (1994) Glutamate exocytosis and MARCKS phosphorylation are enhanced by a metabotropic glutamate receptor coupled to a protein kinase C synergistically activated by diacylglycerol and arachidonic acid. *J Neurochem* 63:1303–1310.
- Dudek SM, et al. (2010) Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function. *Mol Biol Cell* 21:4042–4056.
- Wu HM, Yuan Y, Zawieja DC, Tinsley J, Granger HJ (1999) Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. *Am J Physiol* 276:H535–H542.
- Wojciak-Stothard B, Ridley AJ (2002) Rho GTPases and the regulation of endothelial permeability. *Vascu Pharmacol* 39:187–199.